Next Investors logo grey

Milestone Pod gets academic validation

Published 18-JUL-2016 13:26 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

The Milestone Pod is heading to the lab, with Melbourne’s LaTrobe University to use the tech to inform a study which will be among “the first of its kind”.

Victory Mines’ (ASX:VIC) RTO target Milestone Sports has managed to tie up an arrangement with the university which will see the university gain access to Milestone’s pod to measure biomechanics of new runners.

The pod will be used by volunteers who are starting out on a beginning running program, measuring things such as rate of impact, cadence, and foot strike.

The benefit for the university is that the pod can be worn outside of the lab – meaning it will get much more real-world data than is usually the case in studies of this nature – where the subjects are usually run around on treadmills.

For VIC, it means that tech is trusted enough to form the basis of an academic study – the results of which will also help better inform an algorithm Milestone has which can reportedly predict when shoes are about to wear out.

The study will be carried out by the university’s College of Science, Health, and Engineering and is being led by Dr Christian Barton – a leading clinician with 10 years of clinical experience.

He will also be working with Milestone’s director of research, Dr Stephen Suydam.

A woman running

A woman running

The findings of the study will also reportedly help guide VIC on the next leg of its product development.

Dr Barton says Milestone was selected as a partner because the tech offering was too enticing to pass up.

“The technology is the first of its kind that is available at an affordable rate, making it highly attractive to us and its ease of use is also expected to encourage participation from volunteers, which has previously been more challenging in this type of study,” he said.

There is no guarantee that this study will yield positive results, and VIC remains a speculative stock. Please seek professional advice before deciding whether or not to invest.

More on Victory Mines and Milestone Sports

VIC is in the middle of a reverse takeover of Milestone Sports, which has developed a shoe-worn sensor which is designed as a clip-and-go solution, which measures metrics such as foot strike, cadence, rate of impact, and leg swing.

This differs from other similar products on the market as it actively measures these metrics to give the user feedback on running style – instead of simply using GPS data to tell a user how far they’ve run.

The upshot is that Milestone is able to use its analytics platform to tell a user how to improve their run and diagnose problems rather than simply telling a user how far they’ve run.

Milestone has also opened the system up to retailers, meaning they will have insight into when a user may potentially need a new pair of running shoes – giving the retailer another shot at creating a loyal customer rather than losing them entirely after the first transaction.

It recently announced a move into the $116 billion healthcare market – aiming to use its tech to predict falls for at-risk people.

It says it is confident that by analysing the data from the device it would be able to accurately predict when a person is at risk of a fall.

This can then be sent as an alert to a healthcare provider.

VIC told its shareholders at the time that in the US alone the indirect cost of falls in 2013 reached up the $US30 billion ($A40.16 billion), according to the US Centres for Disease Control and Prevention.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.